RA Capital Management, L.P., Director, 10% Owner at Artiva Biotherapeutics, Inc. (ARTV), bought 6,510,416 shares at $11.52 ($75.0M) on 2026-05-11, disclosed to the SEC on 2026-05-13.
RA Capital Management executed the largest insider purchase in Artiva's history, buying $75M of shares at $11.52, signaling confidence in the company's pivot to rheumatoid arthritis. This rare reversal comes as the stock has pulled back 15.96% over the last five days despite a massive 161.9% gain over the past quarter.
ARTV trades at $10.45, down 15.96% over the last five days despite a 161.9% surge over the past 90 days, and remains 27.81% below its 52-week high of $14.475.
Upcoming catalysts include H1 efficacy data presentation at the Needham Healthcare Conference on April 15, 2026, and a 2026 RA data update from TD Cowen on March 4, 2026.
Risks include a short interest of 2.27% of the float and a recent history of CEO selling, which previously triggered negative sentiment shifts.
Nothing distinguishes this filing.
| Filing → |
| ARTV | BUY | 2026-07-31 | $456K | — | Filing → |
| ARTV | BUY | 2026-07-28 | $413K | — | Filing → |
| ARTV | BUY | 2026-07-23 | $2.6M | — | Filing → |